STAT3 and prostate carcinoma: Moreover, co-targeting PIM and EGFR using M-110 or SGI-1776 with gefitinib showed a synergistic effect on cell proliferation.112 This combination approach has also been shown in non-small-cell lung cancer (NSCLC), where AZD-1208 and osimertinib (an EGFR inhibitor) elicited synergistic effects with respect to cell viability and phosphorylation of STAT3 (ref. 115), which, if replicated in PCa, could prevent STAT3-driven promotion of aggressive prostate cancer features.86